KYNB · Current Report (Form 8-K) · Filed January 7, 2026

Kyntra Bio Inc — 8-K exhibit

fgen-ex3_1.htm

EX-3.1

Exhibit 3.1

Certificate of Amendment

of the Amended and Restated Certificate of Incorporation

of FibroGen, Inc.

FibroGen, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, hereby certifies that:

First: The current name of the corporation is FibroGen, Inc.

Second: The date of filing of the original Certificate of Incorporation of FibroGen, Inc. with the Secretary of State of the State of Delaware was September 29, 1993 and the date of filings of the Amended and Restated Certificate of Incorporation of the Company with the Secretary of State of the State of Delaware was November 19, 2014 and Certificate of Amendment of the Amended and Restated Certificate of Incorporation on June 10, 2025.

THIRD: The FIRST Article of the Amended and Restated Certificate of Incorporation is hereby further amended to read in its entirety as follows:

“The name of this corporation is Kyntra Bio, Inc. (the “Company”).”

FOURTH: This Certificate of Amendment shall be effective at 4:30 p.m. Eastern Time on January 7, 2026.

IN WITNESS WHEREOF, said corporation has caused this Certificate of Amendment to be signed by its Chief Executive Officer this 29th day of December, 2025.





By:	/s/ Thane Wettig
Thane Wettig
Chief Executive Officer

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer